Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 11/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530625 | 0.85 | CCNE1 (0.49) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3527302 | 0.82 | BTK (0.38) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3528302 | 0.81 | CCNE1 (0.38) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3022172 | 0.81 | CCNE1 (0.43) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3022176 | 0.81 | CCNE1 (0.43) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3531999 | 0.79 | CCNE1 (0.45) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3524371 | 0.79 | CCNE1 (0.46) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL3526593 | 0.77 | CCNE1 (0.38) | IRAK4CCNE1CDK2FLT3SYK | |
| SCHEMBL14547375 | 0.74 | CDK2 (0.53) | CCNE1CDK2FLT3 | |
| SCHEMBL4128726 | 0.71 | KDM4E (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | IRAK4 998/4885CCNE1 538/4885CDK2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.